ArticleArthritis research & therapy2018
The epidemiology of psoriatic arthritis in Israel - a population-based study.
Article in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 55 citations in OpenAlex.
- Stopping or continuing chronic antihypertensive therapy during hospitalization.Journal of internal medicine · 2026Article
- The Association Between SARS-CoV-2 Exposure, COVID-19 Vaccination and Psoriatic Arthritis-A Nested Case-Control Study.Vaccines · 2026Article
- Global epidemiology of spondyloarthritis.Nature reviews. Rheumatology · 2025Review
- Psoriatic arthritis incidence and prevalence trajectory in Poland-public-payer, national-level, long-term data.Rheumatology international · 2025Article
- Glycosylation Pattern of Serum Clusterin in Psoriatic Arthritis and Rheumatoid Arthritis-The Search for New Diagnostic Glycomarkers.International journal of molecular sciences · 2024Article
- Prevalence and Incidence of Psoriatic Arthritis among Patients with Psoriasis and Risk Factors for Psoriatic Arthritis in Republic of Korea: A Nationwide Database Cohort Study.Acta dermato-venereologica · 2024Article
- Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis.Drugs & aging · 2024Article
- Epidemiological trends in psoriatic arthritis: a comprehensive population-based study.Arthritis research & therapy · 2024Article
- COVID-19 Vaccine Effectiveness among Patients with Psoriatic Disease: A Population-Based Study.Vaccines · 2024Article
- The risk factors for uveitis among psoriatic arthritis patients: a population-based cohort study.Clinical rheumatology · 2024Article
- Trends in Pregabalin Use and Prescribing Patterns in the Adult Population: A 10-Year Pharmacoepidemiologic Study.CNS drugs · 2024Article
- The Risk of Herpes Zoster Events in Patients with Spondyloarthritis and the Effect of BNT162b2 mRNA COVID-19 Vaccine.Vaccines · 2024Article
- The incidence of vasculitides in Israel from 2007 to 2021 and during the COVID-19 pandemic.Therapeutic advances in musculoskeletal disease · 2024Article
- Predictive factors of psoriatic arthritis in a diverse population with psoriasis.The Journal of international medical research · 2024Article
- Prevalence of psoriatic arthritis in Italy: insights from the multicentric MAPSI study.Frontiers in medicine · 2024Article
- Evaluation of a machine learning tool for the early identification of patients with undiagnosed psoriatic arthritis - A retrospective population-based study.Journal of translational autoimmunity · 2023Article
- Paradoxical Effects of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center.Journal of psoriasis and psoriatic arthritis · 2023Article
- Prescription Trends of Biologic DMARDs in Treating Rheumatologic Diseases: Changes of Medication Availability in COVID-19.Journal of personalized medicine · 2023Article
- Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis.Biologics : targets & therapy · 2023Article
- Sex- and gender-related differences in psoriatic arthritis.Nature reviews. Rheumatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited information on the epidemiology of psoriatic arthritis (PsA) in general and in Middle Eastern populations in particular. The aims of this study were to estimate the prevalence and incidence rates of PsA and their temporal trends in the general population in Israel.
methodsIn this study, a cohort of adult patients with PsA was derived from the database of Clalit Health Services (CHS), Israel's largest health fund, with over 4.4 million members. The crude and age- and sex-standardized prevalence and incidence rates of PsA from 2006 to 2015 in the general population were calculated. The variation in PsA prevalence was assessed in relation to several demographic factors.
resultsAmong the 2,931,199 individuals aged 18 years and older registered in the CHS database in 2015, 4490 patients had a diagnosis of PsA (322 incident cases), resulting in overall crude prevalence and incidence rates of 0.153% (95% CI 0.149%, 0.158%) and 10.9 (95% CI 9.8, 12.3) per 100,000 population, respectively. The reported prevalence of PsA in Israel has doubled between 2006 and 2015 (from 0.073% to 0.153%). In contrast, the global incidence rate remained stable, with a gradual increase in incidence among individuals aged 51 to 70 years. PsA is associated with Jewish ethnicity, high socioeconomic status, and higher body mass index.
conclusionsThe prevalence and incidence of PsA in Israel are within the range of previous estimates from Southern European populations. An increase in the reported prevalence of PsA was observed over the past decade in the general population in Israel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.